RVMD Stock Recent News
RVMD LATEST HEADLINES
Revolution Medicines, Inc. (RVMD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Revolution Medicines is a clinical-stage biotech. The company has nearly a million in cash to develop its deep pipeline.
Interim Data to be Presented for RMC-6236 (RAS MULTI (ON) Inhibitor) and RMC-6291 (RAS G12C (ON) Inhibitor)
Revolution Medicines, Inc. has a diversified pipeline of drugs but is still searching for its flagship project, making it a high-risk investment. The company is focusing on developing RAS(ON) inhibitors, which target the active form of KRAS, with several promising candidates in development. Revolution Medicines has a strong financial position with almost $2 billion in cash, but its current valuation may not be justified without meaningful clinical data.
Revolution Medicines, Inc. (NASDAQ:RVMD ) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Erin Graves – Senior Director of Corporate Communications and Investor Relations Mark Goldsmith – Chairman and Chief Executive Officer Jack Anders – Chief Financial Officer Steve Kelsey – President of Research & Development Conference Call Participants Marc Frahm – TD Cowen Faisal Khushid – Leerink Partners Jay Olson – Oppenheimer Ami Fadia – Needham Alec Stranahan – Bank of America Ben Burnett – Stifel Operator Good day and thank you for standing by. Welcome to Revolution Medicine's Second Quarter 2023 Earnings Conference Call.
Revolution Medicines, Inc. is undoubtedly doing interesting science. However, I can name 10 companies that are doing equally interesting science but are valued at a fifth of Revolution Medicines stock. There is no way their early data justifies that nearly $3bn valuation.
REDWOOD CITY, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will be a featured speaker at the Goldman Sachs 44th Annual Global Healthcare Conference and in Barclays' ongoing series of virtual lunchtime fireside chats.
Revolution Medicines, Inc. (NASDAQ:RVMD ) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ET Company Participants Erin Graves - Senior Director of Corporate Communications and Investor Relations Mark Goldsmith - Chairman, President & Chief Executive Officer Steve Kelsey - President of Research & Development Jack Anders - Chief Financial Officer Conference Call Participants Marc Frahm - TD Cowen Eric Joseph - JPMorgan Chase & Co. Michael Schmidt - Guggenheim Partners Benjamin Burnett - Stifel Jay Olson - Oppenheimer & Co. Ami Fadia - Needham & Company Jonathan Chang - SVB Securities Operator Good day and welcome to Revolution Medicine's First Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, today's conference is being recorded.
Revolution Medicines, Inc. (RVMD) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.78 per share a year ago.
The average of price targets set by Wall Street analysts indicates a potential upside of 27.2% in Revolution Medicines, Inc. (RVMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.